Search

Displaying results 4171 - 4180 of 9670 in total
  1. Drug

    ISA101b

    go.drugbank.com/drugs/DB18694
    Investigational

    ISA101b (peltopepimut-S) is a therapeutic vaccine against the HPV-specific E6/E7 oncoproteins.

  2. Drug

    Gadoquatrane

    go.drugbank.com/drugs/DB33282
    Approved

    [L63814] Like other gadolinium agents it is paramagnetic, developing a magnetic moment in the scanner's field that alters the relaxation of nearby water protons and brightens tissues with abnormal vascularity

  3. Drug

    Isaralgagene civaparvovec

    go.drugbank.com/drugs/DB16808
    Investigational

    Isaralgagene civaparvovec, formerly known as ST-920, is liver-tropic rAAV 2/6 vector carrying the cDNA for human alpha-galactosidase A (α-Gal A) enzyme. … It is developed by Sangamo Therapeutics and investigated in Fabry Disease.

  4. Drug

    Cochliobolus spicifer

    go.drugbank.com/drugs/DB10818
    Approved

    Cochliobolus spicifer is a fungus which can provoke allergic reactions. Cochliobolus spicifer extract is used in allergenic testing.

    Mixtures: Treatment Set TS128871
  5. Drug

    Tolpropamine

    go.drugbank.com/drugs/DB13305
    Experimental

    Categories: Antihistamines, Anesthetics, Etc.
  6. Drug

    Tositumomab

    go.drugbank.com/drugs/DB00081
    ApprovedWithdrawn

    It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine).

  7. Drug

    CD68-ET3-LV

    go.drugbank.com/drugs/DB32864
    Investigational

    CD68-ET3-LV is an autologous gene therapy consisting of CD34+ hematopoietic stem and progenitor cells transduced ex-vivo with the CD68-ET3-LV lentiviral vector.

  8. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    It was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively.

  9. Drug

    Dichloroacetic acid

    go.drugbank.com/drugs/DB08809
    ApprovedInvestigationalWithdrawn

    DCA was approved for use in Canada in 1989 (as a topical formulation for treatment of warts and for cauterization and removal of a wide variety of skin and tissue lesions), but was cancelled post market … Salts of DCA are used as drugs since they inhibit the enzyme pyruvate dehydrogenase kinase.

  10. Drug

    Oxyphenisatin

    go.drugbank.com/drugs/DB04823
    ApprovedWithdrawn

    It may cause jaundice.